



## **Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Finalist in Greater Washington**

May 8, 2009

ROCKVILLE, Md.--(BUSINESS WIRE)--May. 8, 2009-- Emergent BioSolutions Inc. (NYSE:EBS) announced today that its chairman and chief executive officer, Mr. Fuad El-Hibri, is a finalist for the Ernst & Young Entrepreneur of the Year<sup>®</sup> 2009 Award in the Greater Washington region. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Mr. El-Hibri was selected as a finalist from nearly 100 nominations by a panel of independent judges. Award winners will be announced at a special gala event on June 18 at the Ritz-Carlton, Tysons Corner in Virginia.

"It is an honor to be chosen as a finalist for the Ernst & Young Entrepreneur of the Year Award," said Mr. Fuad El-Hibri. "I am proud of the entrepreneurial spirit, commitment, and collaboration that prevail at Emergent, which are key factors to our company's success. This recognition represents the contributions of each and every member of the Emergent Team as we work together in pursuit of our company mission – to protect life."

Mr. El-Hibri was also a finalist for the Greater Washington region in 2007. The Ernst & Young Entrepreneur of the Year awards program celebrates its 23rd anniversary this year. The program has expanded to recognize business leaders in over 135 cities in 50 countries throughout the world.

### **About Emergent BioSolutions Inc.**

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax<sup>®</sup> (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent's development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com).

### **About Ernst & Young's Entrepreneur of the Year<sup>®</sup> Awards Program**

Ernst & Young's Entrepreneur of the Year<sup>®</sup> Award is the world's most prestigious business award for entrepreneurs. The award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, the Ernst & Young Entrepreneur of the Year<sup>®</sup> award celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries.

### **Sponsors**

Founded and produced by Ernst & Young LLP, the Entrepreneur of the Year awards are pleased to have the Ewing Marion Kauffman Foundation and SAP America as national sponsors.

In Greater Washington, sponsors include HSBC Bank, Pillsbury Law, Reznick Group, Lockton Companies and the Washington Business Journal.

Source: Emergent BioSolutions Inc.

### **Emergent BioSolutions Inc.**

#### **Investors Contact:**

Robert G. Burrows  
Vice President, Investor Relations  
**301-795-1877**

[BurrowsR@ebsi.com](mailto:BurrowsR@ebsi.com)

or

#### **Media Contact:**

Tracey Schmitt  
Vice President, Corporate Communications  
**301-795-1800**

[SchmittT@ebsi.com](mailto:SchmittT@ebsi.com)